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Hyperandrogenemia Predicts Metabolic Phenotype in
Polycystic Ovary Syndrome: The Utility of Serum
Androstenedione
Michael W. O’Reilly, Angela E. Taylor, Nicola J. Crabtree, Beverly A. Hughes,
Farfia Capper, Rachel K. Crowley, Paul M. Stewart, Jeremy W. Tomlinson,*
and Wiebke Arlt*†
Context: Polycystic ovary syndrome (PCOS) is a triad of anovulation, insulin resistance, and hy-
perandrogenism. Androgen excess may correlate with metabolic risk and PCOS consensus criteria
define androgen excess on the basis of serum T. Here we studied the utility of the androgen
precursor serum androstenedione (A) in conjunction with serum T for predicting metabolic dys-
function in PCOS.
Patients and Methods: Eighty-six PCOS patients fulfilling Rotterdam diagnostic consensus criteria
and 43 age- and bodymass index-matched controls underwentmeasurement of serum androgens
by tandem mass spectrometry and an oral glucose tolerance test with homeostatic model assess-
ment of insulin resistance and insulin sensitivity index calculation. We analyzed 24-hour urine
androgen excretion by gas chromatography/mass spectrometry.
Results: PCOS patients had higher levels of serum androgens and urinary androgen metabolites
than controls (all P .001).Within the PCOS cohort, both serumA and Twere positively correlated
with the free androgen index (T  100/SHBG) and total androgen metabolite excretion (all P 
.001). All subjects with T above the normal reference range [high T (HT)] also had high A (HA/HT
group, n 56). However, the remaining 30 patients had normal T levels, either in the presence of
HA (HA/NT; n 20) or normalA (NA/NT; n 10). Thegroups did not differ in ageor BMI. TheHA/HT
and HA/NT groups had higher total androgen excretion than NA/NT (P  .01 and P  .05, respec-
tively). Multiple linear regression showed a strong negative association between serum andro-
stenedione and insulin sensitivity. The incidence of dysglycemia according to an oral glucose tol-
erance test increased with the severity of androgen phenotype (NA/NT, 0%; HA/NT, 14%; HA/HT,
25%, P  .03).
Conclusion: Simultaneous measurement of serum T and A represents a useful tool for predicting
metabolic risk in PCOSwomen.HA levels are a sensitive indicator of PCOS-related androgenexcess.
(J Clin Endocrinol Metab 99: 1027–1036, 2014)
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Abbreviations: A, androstenedione; AEAnov, androgen excess and anovulation;
AEAnovPCO, androgen excess, anovulation, and polcystic ovaries on ultrasound; An,
androsterone; AnovPCO, anovulation and polcystic ovaries on ultrasound; BMI, body
mass index; CI, confidence interval; DHEA, dehydroepiandrosterone; DHEAS, DHEA sul-
fate; DXA, dual-energy x-ray absorptiometry; Et, etiocholanolone; FAI, free androgen in-
dex; GC/MS, gas chromatography/mass spectrometry; HA/HT, high A and also T above the
normal reference range; HA/NT, high A and normal T levels; HOMA-IR, homeostasis model
assessment of insulin resistance; 11-HSD1, 11-hydroxysteroid dehydrogenase type 1;
17-HSD5, 17-hydroxysteroid dehydrogenase type 5; ISI, insulin sensitivity index; LC/
MS-MS, liquid chromatography/tandemmass spectrometry; NA/HT, normal A and T above
the normal reference range; NA/NT, normal A and normal T levels; OGTT, oral glucose
tolerance test; PCOS, polycystic ovary syndrome; THE, tetrahydrocortisone; 5-THF/THF,
5-tetrahydrocortisol to tetrahydrocortisol; 5-THF  THF, tetrahydrometabolites of
cortisol.
O R I G I N A L A R T I C L E
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Polycystic ovary syndrome (PCOS) is defined by a clin-ical triad of anovulation, insulin resistance, and an-
drogen excess (1). It has an estimated prevalence of 5%–
10% in women of reproductive age and consumes most
assisted conception health care budgets (2, 3). Diagnostic
criteria for PCOS have changed significantly in recent
years, acknowledging the heterogeneity of clinical pheno-
type (4, 5). The long-term health consequences of PCOS
are increasingly recognized, ranging from metabolic dys-
function to increased cardiovascular events (6–8).Andro-
gen excess remains the cardinal clinical feature thatdefines
the condition and may contribute at least in part to the
adverse metabolic phenotype.
However, a lack of clarity persists on which androgens
should be measured, what constitutes normal reference
ranges, andwhich analytical technique should be used (9).
Equally we have little insight into whether different pat-
terns of biochemical hyperandrogenemia define distinct
PCOS subgroups in terms of metabolic risk. The most
accurate strategy for quantification of biochemical andro-
gen excess in PCOS is the measurement of total 24-hour
urinary androgenmetabolite excretion (10); however, uri-
nary steroid profiling by gas chromatography/mass spec-
trometry (GC/MS) is time consuming and expensive. In
routine clinical practice, serum total T remains the most
commonly measured and widely available marker for the
estimation of biochemical androgen excess (2). However,
the measurement of T is severely limited by a number of
factors including the following: 1) T circulates bound to
SHBG and other proteins such as albumin, and only the
unbound or free fraction enters into target tissues (11); 2)
the measurement of free T by direct RIA is highly inaccu-
rate (12); 3) direct immunoassays for total T are highly
variable (13); and 4) T circulates in low nanomolar range
concentrations, with the lower end of the normal female
reference rangebelow the limit of quantitation inall assays
available.
Androgen excess in PCOS originates from the ovaries
and adrenals (14);moreover, increased peripheral conver-
sion of T to the most potent androgen 5-dihydrotestos-
terone by systemically up-regulated 5-reductase activity
has been well documented (15, 16). Androstenedione (A)
is the immediate precursor of T. In addition to direct se-
cretion by ovaries and adrenals, A can be generated in
peripheral tissues from its precursor dehydroepiandros-
terone (DHEA) by the enzyme 3-hydroxysteroid dehy-
drogenase type 2 (17). In addition to mainly ovarian pro-
duction, about 25% of plasma T derives from the
conversion fromAby17-hydroxysteroiddehydrogenase
type 5 (17-HSD5 or AKR1C3) in adipose and other pe-
ripheral tissues (18). SerumAis inconsistentlymeasured in
routine clinical investigation of suspected PCOS because
clinicians remain uncertain about its diagnostic value.
Limited previous work suggests that 10% of PCOS pa-
tients may be misclassified as normoandrogenemic if A is
not measured (19).
The independent health risks of androgen excess in
women are increasingly apparent (20). We therefore hy-
pothesized that patients with the coelevation of A and T
and therefore increased circulating androgen burden rep-
resent a distinct subgroup with adverse metabolic param-
eters compared with those with normal androgens or sol-
itary elevation of either A or T.We thus also hypothesized
thatA represents amore sensitivemarker for the biochem-
ical detectionof androgen excess.We therefore carriedout
a detailed analysis of androgen synthesis and metabolism
to test these hypotheses in a large cohort of women with
PCOSaccording toRotterdamcriteria in comparisonwith
a group of body mass index (BMI)-matched healthy
controls.
Materials and Methods
Subjects
Women with PCOS were recruited from outpatient clinics at
the Queen Elizabeth Hospital Birmingham and Birmingham
Women’s Hospital. This observational, cross-sectional study
was approved by the South Birmingham Research Ethics Com-
mittee, and all participants gave their written informed consent.
PCOS was diagnosed according to the Rotterdam European So-
ciety of Human Reproduction and Embryology 2004 criteria,
with the presence of two or more of the following: oligo-/an-
ovulation, clinical signs of hyperandrogenism, and polycystic
ovaries on ultrasound (4). Other causes of oligomenorrhea and/or
androgen excess were excluded by history, physical examination,
and biochemical assessment. Healthy controls were recruited via
local advertisement, with a diagnosis of PCOS excluded by clinical
and biochemical parameters. Exclusion criteria for both groups
were current or recent treatment with glucocorticoids, congenital
adrenal hyperplasia, hyperprolactinemia, thyroid dysfunction,
pregnancy, age younger than 18 or older than 45 years, oral con-
traceptive use within 3 months prior to recruitment, and diabetes
mellitus.
Clinical protocol
Participants attended the National Institute of Health Re-
search/Wellcome Trust Clinical Research Facility at the Queen
Elizabeth Hospital Birmingham after an overnight fast. Each
Centre for Endocrinology, Diabetes, and Metabolism (M.W.O., A.E.T., B.A.H., R.K.C., P.M.S., J.W.T., W.A.), School of Clinical and Experimental Medicine, University of Birmingham,
Edgbaston, Birmingham B15 2TT, United Kingdom; Department of Nuclear Medicine (N.J.C.), University Hospitals Birmingham, Edgbaston, and National Institute of Health Research/
Wellcome Trust Clinical Research Facility (F.C.), University Hospitals BirminghamNational Health Service Foundation Trust, Birmingham B15 2TH, United Kingdom; and University of Leeds
(P.M.S.), Leeds, LS2 9NL, United Kingdom
1028 O’Reilly et al Androstenedione and Metabolic Disease in PCOS J Clin Endocrinol Metab, March 2014, 99(3):1027–1036
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 28 March 2014. at 05:11 For personal use only. No other uses without permission. . All rights reserved.
patient provided a 24-hour urine sample for urinary steroid me-
tabolite analysis byGC/MS as previously reported (21). Baseline
anthropometric assessment included height, weight, BMI (kilo-
grams per square meter), and blood pressure measurement. A
modified Ferriman-Gallwey scoring system for hirsutism was
used as described previously (22). Dual-energy x-ray absorpti-
ometry (DXA) was used for body composition assessment using
a Hologic Discovery/W DXA (software version Apex 3.0; Ho-
logic Inc). Specific fat phenotype was measured using android,
gynecoid, peripheral (arms and legs), and trunk regions of in-
terest, with subsequent calculation of android to gynecoid and
trunk to peripheral fat ratios (23).
Blood samples were drawn for fasting plasma glucose and
insulin and serumT,A,DHEA,DHEA sulfate (DHEAS), SHBG,
FSH and LH, total cholesterol, high-density lipoprotein, and
triglycerides. Each participant underwent a 75-g oral glucose
tolerance test (OGTT) with blood sampling at 30-minute inter-
vals for 2 hours. Glucose and insulin weremeasured usingmeth-
ods described previously (24). Subjects were categorized as hav-
ing normal glucose tolerance or dysglycemia on the basis of
2-hour glucose values (normal glucose tolerance 7.8 mmol/L,
dysglycemia 7.8 mmol/L). Homeostasis model assessment of
insulin resistance (HOMA-IR) was calculated using the follow-
ing formula: [fasting glucose (millimoles per liter) * fasting in-
sulin (milliinternational units per liter)/22.5]. Insulin sensitivity
index (ISI) was calculated using the following formula:
ISI [75 000 (glucose0 glucose120) 1.15 180 0.19
body weight (kg)]/120 log (insulinmean) glucosemean](mgl2
mmol1mIU1.min1) (25, 26).
Serum and urine steroid measurements
Serum steroids were measured by liquid chromatography/
tandem mass spectrometry (LC/MS-MS) using a Waters Xevo
mass spectrometer with Acquity uPLC system. LC/MS-MS con-
ditions were an electrospray ionization source with capillary
voltage4.0kV, a source temperatureof150°C, andadesolvation
temperature of 500°C. Serum steroid oxime analysis, which fa-
cilitates enhanced detection by formation of oximederivatives of
the steroid oxogroups (27), was used for the measurement of T,
A, and DHEA and carried out in positive mode, whereas the
measurementof serumDHEASwasperformed innegativemode.
T, A, and DHEA were extracted from 200 L serum via liquid-
liquid extraction using 1mL tert-butyl-methyl-ether followed by
derivatization into steroid oximes using 100 L derivatization
mixture (0.16 g hydroxylamine in 8 mL pyridine). For protein
precipitation and extraction of DHEAS, 20LZnSO4, 0.1mM,
and 100L acetonitrile were added to 20L serumbefore evap-
oration under constant nitrogen flow (28). All steroids were sep-
arated using an optimized gradient system consisting of metha-
nol with 0.1% formic acid and quantified referring to a linear
calibration series with appropriate internal standards. Each ste-
roid was identified by matching retention times and two mass
transitions in comparison with a deuterated reference compound.
Serum A and T were categorized as normal based on locally
derived LC/MS-MS reference values for premenopausal women
(T, 0.3–1.9 nmol/L; A, 1.4–7.4 nmol/L; percentiles of 2.5th to
97.5th of an unselected healthy female control cohort). Serum
androgens were used to categorize PCOS patients into four sub-
groups: normal A/normal T (NA/NT), high A/normal T (HA/
NT), normal A/high T (NA/HT), and high A/high T (HA/HT).
The free androgen index (FAI) was calculated using the formula
(T * 100)/SHBG.We also subdivided the PCOSpatients into the
four phenotypic subgroups arising from the Rotterdam criteria
(29) as recommended at a recent National Institutes of Health
meeting (3). These subgroups are defined by the presence of the
following: 1) androgen excess, anovulation, and polcystic ova-
ries on ultrasound (AEAnovPCO), 2) AnovPCO, 3)
AEPCO and 4) AEAnov.
Urinary steroidmetabolite excretion analysis was carried out
by GC/MS as described previously (21). The sum of andros-
terone (An) and etiocholanolone (Et) was considered represen-
tative of active androgenmetabolite excretion (10).Net systemic
5-reductase activity was assessed by the ratios of An to Et and
5-tetrahydrocortisol to tetrahydrocortisol (5-THF/THF).
11-hydroxysteroid dehydrogenase type 1 (11-HSD1) activity
was estimated using the ratio of the tetrahydrometabolites of
cortisol (5-THF  THF) to tetrahydrocortisone (THE) (30),
and 11-hydroxysteroid dehydrogenase type 2 (11-HSD2) ac-
tivity by the ratio of free urinary cortisol to cortisone. Total
glucocorticoid metabolite excretion was assessed as the sum of
5-THF  THF  THE  cortolones  cortols  cortisol 
cortisone.
Statistical analysis
The Statistical Package for the Social Sciences (SPSS) version
21 was used for data analysis. All data are expressed as mean
SD unless otherwise stated. Independent-samples t tests or
Mann-WhitneyU tests were used as appropriate for comparison
between two groups. One-way ANOVA with post hoc Tukey
testing was used for multiple comparisons between different
groups. Correlation testing was performed using Pearson’s cor-
relation coefficient or Spearman’s test as appropriate. Multiple
linear regression was used to adjust for the confounding effects
of different variables. Differences were considered statistically
significant at P  .05.
Results
Baseline clinical and metabolic characteristics of PCOS
and age- and BMI-matched healthy controls are shown in
Table 1. Complete clinical, biochemical, and radiological
datawere available in 86womenwith PCOS.Resultswere
compared with those obtained from 43 age- and BMI-
matched controls. Hirsutism, oligomenorrhea, and poly-
cystic ovaries were present in 87%, 92%, and 73% of
PCOS patients, respectively. Polycystic ovary subgroups
arising from the Rotterdam criteria were matched for age
and BMI and categorized as follows: 1) AEAnovPCO
(n 51, 59%); 2) AEPCO (n 6, 7%); 3) AnovPCO
(n  9, 11%); and 4) AEAnov (n  20, 23%).
Circulating androgens and androgen excretion
Both serum A and T were significantly higher in PCOS
than in healthy controls (P  .0001 for both, Table 1).
PCOS patients also had significantly higher FAI, DHEA,
and DHEAS (all P .0001) than controls. Total 24-hour
urinary androgen excretion was also significantly higher
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in PCOS (P .0001, Table 2), with higher excretion ofAn
(P  .001), Et (P  .05), and DHEA (P  .05). T and A
correlated strongly with FAI and total androgen metabo-
lite excretion (Figure 1, A–D).
Serum A was elevated in 76 of 86 PCOS patients
(88.3%); T was elevated in 56 (65.1%). A and T were
elevated in 1 of 43 (2.3%) and 5 of 43 (11.6%) healthy
controls, respectively. Serum levels of A and T were in the
normal range in 10 and 30 PCOS patients, respectively.
Patients with PCOS were subsequently divided into four
androgen phenotype groups dependent on circulating an-
drogens; NA/NT, NA/HT, HA/NT, and the most severe
degree of androgen excess, HA/HT. Most patients were
categorized as HA/HT (n  56), with 20 and 10 patients
classified as HA/NT and NA/NT, respectively; no patient
had high T but normal A (Figure 2).
Serum androgen levels in the PCOS women with the
mildest degree of biochemical androgen excess (NA/NT)
were similar to those in healthy BMI-matched controls
(Table 1). However, they differed significantly from con-
trols with regard to SHBG and FAI. NA/NT women had
androgen excretion rates similar to controls, whereas an-
drogen excretion in the two other PCOS groups was sig-
nificantly higher (Table 2 andFigure 3A). Similarly, serum
DHEA and DHEAS were significantly higher in HA/HT
andHA/NT patients as compared with the NA/NT group
and the controls (Figure 3, E and F). The Ferriman-Gall-
wey scorewas significantly higher inHA/HTwomen com-
pared with NA/NT (P  .04) (Table 1).
Metabolic characteristics
Overall, PCOS patients had higher fasting insulin and
HOMA-IRvalues thanBMI-matched controls, but fasting
glucose and 2-hour values did not differ significantly (Ta-
ble 1). The incidence of dyglycemia was 19.7% in the
PCOS group compared with 6.9% in controls (P  .03)
(Table 1). BMI was positively correlated with FAI (R 
0.4,P .0001) and systemic 5-reductase activity (An/Et,
R 0.21, P .01; 5-THF THF, R 0.20, P .02).
ISI values were lower in PCOS patients compared with
controls (P .001, Table 1). The ISI had a strong negative
correlationwith serumTandA (R0.41,P .001, and
R0.55, P .00001, respectively, Figure 1, E and F).
When PCOS and control patients were considered sepa-
Table 1. Clinical, Biochemical, and Metabolic Characteristics in the Overall PCOS Cohort (n  86), PCOS Androgen
Phenotype Subgroups, and Age- and BMI-Matched Controls (n  43)
Variable
Controls
(n  43)
All PCOS
(n  86)
NA/NT
(n  10)
HA/NT
(n  20)
HA/HT
(n  56)
Age, y 32.4  9.8 30.0  7.2 32.9  2.9 30.8  7.9 28.8  7.0
BMI, kg/m2 30.3  6.4 31.9  7.1 30.2  6.5 30.0  5.9 32.1  6.5
Ferriman-Gallwey score 2.1  1.6 12.4  6.7a 9.9  5.3a 10.1  6.4a 13.9  7.2a,b
T, nmol/L 1.3  0.4 2.2  0.8a 1.2  0.3 1.6  0.4 2.6  0.7a,b
FAI (T  100/SHBG) 3.2  1.8 9.1  6.1a 5.5  3.9d 7.3  4.6d 10.5  6.5a,b
SHBG, nmol/L 49.8  26.6 32.3  18.4a 28.8  11.8a 30.8  21.2a 31.8  16.5a
A, nmol/L 3.5  1.4 13.4  5.6a 5.1  1.7 11.4  4.2a,c 14.2  5.1a,c
DHEA, nmol/L 20.5  7.9 57.5  30.0a 24.4  8.6 59.8  34.8a,e 58.0  26.8a,e
DHEAS, mol/L 3.9  2.0 6.2  3.0a 2.4  1.2 6.3  2.6c 6.2  2.7a,c
DHEA to DHEAS ratio 7.8  3.7 12.9  6.8d 12.6  8.5d 14.0  10.0d 15.4  5.4d
LH, IU/L 5.2  2.4 9.9  5.8d 4.7  3.2 9.0  6.3d 11.4  9.2b,d
LH to FSH ratio 0.8  0.5 2.0  1.5d 0.9  0.7 2.1  1.9d 2.3  1.4b,d
Fasting glucose, mmol/L 4.6  0.5 4.8  0.7 5.0  0.5 4.7  0.5 4.8  0.8
Two-hour OGTT glucose,
mmol/L
6.7  1.5 6.5  2.2 5.5  1.2 6.7  1.9 6.7  2.3
Fasting insulin, mIU/L 2.0  1.5 10.4  8.6f 8.2  5.5d 11.7  8.3d 12.3  6.6a
HOMA-IR 0.9  0.8 2.3  0.2f 1.9  1.1d 2.4  1.5d 2.8  1.0b,f
ISI (Cederholm),
mg/L2/mmol  mU  min) (25)
78.7  38.0 54.6  24.1a 73.4  54.6 51.0  17.1a,f 54.4  25.2a,f
Dysglycemia, n, % 3 (6.9%) 17 (19.7%)d 0 3 (15%) 14 (25%)b,d
Abbreviation: HOMA-IS, homeostatic model assessment of insulin sensitivity. PCOS subgroup classification according to high (H) or normal (N)
serum A and serum T concentrations as measured by LC/MS-MS [normal T (NT) 1.9 nmol/L; normal A (NA) 7.4 nmol/L]. Data are expressed as
mean  SD unless otherwise stated. Normal glucose tolerance was a 2-hour glucose OGTT 7.7 mmol/L or less. Dysglycemia was a 2-h glucose
OGTT 7.8 mmol/L or greater.
a P  .001 as compared with the BMI-matched healthy controls
b P  .05 as compared with the NA/NT group.
c P  .001 as compared with the NA/NT group.
d P  .05 as compared with the BMI-matched healthy controls.
e P  .01 as compared with the NA/NT group.
f P  .01 as compared with the BMI-matched healthy controls.
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rately, a negative association between A and ISI was ob-
served in both groups (R0.53, P .00001, and R
0.41, P .001, respectively). In obese control patients,
this negative association between A and ISI persists (R 
0.25, P .04). On multiple linear regression analysis, a
significant negative association was confirmed only be-
tween A and ISI [coefficient 2.69, 95% confidence in-
terval (CI)1.57 to3.81, P .0001, Supplemental Ta-
ble 1, published on The Endocrine Society’s Journals
Online web site at http://jcem.endojournals.org]; no such
association was observed between ISI and serum T,
DHEAS, or DHEA.
HOMA-IR in all three PCOS subgroups was signifi-
cantly higher than in controls and HA/HT women had
significantly higher values than NA/NT women (P  .05
for both) (Figure 3B). However, onlyHA/NT andHA/HT
had lower ISI values (Table 1). PCOS women in the
NA/NT group had significantly higher fasting insulin and
HOMA-IR than BMI-matched controls (Table 1). The
rate of dysglycemia in theHA/NTandHA/HTgroupswas
15%and 25%, respectively; noNA/NTwomenwere dys-
glycemic. No significant differences were observed in sys-
tolic blood pressure or lipid profiles between each group.
No difference in insulin sensitivity was observed between
the four phenotypic groups defined by the Rotterdam cri-
teria (Supplemental Figure 1).
Body composition
No significant differences in fat distribution or total
leanmass onDXAwere observed between PCOSand con-
trol women or between the three androgen phenotype or
Rotterdam phenotype groups (see Supplemental Table 2).
The android to gynecoid ratio was strongly correlated
with HOMA-IR (R  0.53, P  .0001), FAI (R  0.37,
P  .0001), An/Et (R  0.38, P  .0001), 5-THF/THF
(R  0.31, P  .0001) and total glucocorticoid metabo-
lites (R  0.26, P  .01). There was a strong negative
correlation between the android to gynecoid ratio and ISI
(R  0.41, P  .01).
Cortisol metabolism
PCOS patients and controls did not differ significantly
in indices of 11-HSD1 or 11-HSD2 activity (Table 2).
However, total glucocorticoid excretion was higher in the
PCOS group (9624 4214 vs 6821 3572 g per 24 h,
P  .01). Urinary glucocorticoid excretion appeared to
gradually increase with the degree of androgen excess,
with significantly higher levels in the HA/HT group than
in controls (Table 2). On multiple linear regression (Sup-
plemental Table 1), total glucocorticoid excretion was a
negative predictor of ISI (coefficient 0.003, 95% CI
0.001 to 0.005, P  .048).
Table 2. Twenty-Four-Hour Urinary Steroid Excretion in PCOS Patients, Controls, and PCOS Androgen Phenotype
Subgroups
Variable
Controls
(n  43)
All PCOS
(n  86)
NA/NT
(n  10)
HA/NT
(n  20)
HA/HT
(n  56)
Total androgen metabolites,
g per 24 h
2882  2018 5493  2781a 2751  1760 4886  1968b,c 5727  2530a,c
An, g per 24 h 1413  906 2824  1651a 1452  1178 2594  1207b 3016  1553a,c
Et, g per 24 h 1468  1208 2457  725a 1299  733 2292  1211 2683  1469b,d
An/Et ratio (5-reductase activity) 1.1  0.4 1.3  0.6b 1.2  0.6 1.3  0.6 1.3  0.6
Urinary DHEA, g per 24 h 457  721 1740  954b 477  400 1586  960 1960  854b,c
Total glucocorticoid metabolites,
g per 24 h
6821  3572 9624  4214e 8449  4181 8935  3404 9803  4390b
5-THF, g per 24 h 940  608 1313  814b 1250  1135 1259  759 1359  842e
THF, g per 24 h 1206  607 1520  549b 1489  924 1477  475 1634  822b
5-THF/THF (5-reductase activity) 0.8  0.3 0.9  0.5 0.8  0.4 0.8  0.5 0.9  0.5
(5-THFTHF)/THE
(11-HSD1 activity)
0.9  0.3 0.9  0.3 0.9  0.3 0.9  0.2 0.9  0.4
Urinary cortisol/urinary cortisone
(11-HSD2 activity)
0.6  0.5 0.6  0.2 0.5  0.1 0.6  0.2 0.7  0.2
Abbreviations: total androgen metabolites, sum of AnEt; total glucocorticoid metabolites, sum of THF5-THFTHEcortolscortolonesfree
cortisol/cortisone. Androgen and glucocorticoid metabolites were measured by GC/MS. The PCOS subgroup classification was according to high
(H) or normal (N) A and T concentrations as measured by LC/MS-MS [normal T (NT) 1.9 nmol/L; normal A (NA) 7.4 nmol/L]. Data are expressed
as mean  SD unless otherwise stated.
a P  .001 as compared with the BMI-matched healthy controls
b P  .05 as compared with the BMI-matched healthy controls.
c P  .05 as compared with the NA/NT group.
d P  .01 as compared with the NA/NT group.
e P  .01 as compared with the BMI-matched healthy controls.
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Discussion
Wehave performed a detailed assessment of the clinical,
metabolic and androgen phenotype of a cohort of
PCOS, revealing that PCOS patients with coelevation of
A andThave impaired indices of insulin sensitivity com-
pared with those with normal androgens or milder hy-
perandrogenemia. Using multiple linear regression, we
found a strong negative relationship between A and in-
sulin sensitivity as measured by the ISI, independent of
age and BMI; such a relationship was not observed for
T. All our patients were diagnosed according to con-
sensus criteria, fulfilling at least two of three criteria.
Until relatively recently, it has been unclear whether
women with hyperandrogenic PCOS are at increased car-
diometabolic risk compared with those without androgen
excess. However, recent data suggest that biochemical an-
drogen excess poses a higher risk of
liver disease, insulin resistance, and
subclinical atherosclerosis compared
with thosewith anovulationandpoly-
cysticovaries alone (20,31,32).These
studies suggest that hyperandrogenic
PCOS represents a distinct metabolic
phenotype, whereas patients without
androgen excess may have a pheno-
type similar to healthy controls (33).
However, in our cohortwe also found
higher fasting insulin values in nor-
moandrogenemic PCOS compared
with healthy controls, suggesting that
women without androgen excess are
not entirely protected from metabolic
dysfunction.
Womenwith hyperandrogenemic
PCOS in our cohort had a signifi-
cantly reduced ISI; those with nor-
mal serum androgens had ISI values
comparable with healthy controls. It
is interesting that HOMA-IR and
homeostatic model assessment of in-
sulin sensitivity values were still un-
favorable in the NA/NT group, sug-
gestive perhaps of impaired fasting
indices but preserved ability to han-
dle an oral glucose load. Further
studies are needed to corroborate
and understand the associations ob-
served here. Serum androgens, and
in particularA, had a strong negative
associationwith the ISI; it is interest-
ing that this association was also ob-
served in control patients with circu-
lating A levels within the normal range. These data lend
support to the hypothesis that metabolic disease in PCOS
should be considered as a continuous variable, with met-
abolic dysfunction observed across a worsening spectrum
of severity of androgen excess. It is important to remember
that normal reference ranges are relatively arbitrarily de-
fined and that androgen exposure across all patients may
contribute to their metabolic phenotype. Women with
normal circulating androgens may still exhibit subtle hy-
perandrogenemia after LH stimulation (34), which could
explain the higher indices of insulin resistance, lower
SHBG, and higher FAI levels observed. The long-term im-
plications of this are unclear without longitudinal, pro-
spective studies, but these findings have also been ob-
servedbyBarber et al (31).Whenwe subdividedourPCOS
cohort into the four phenotypic groups arising from the
A B
C D
E F
Figure 1. A–F, Relationship of serum T and A with FAI, total urinary androgen metabolites, and
ISI. There is a significant positive relationship between both T and A with total androgen
excretion and the FAI; a negative association with ISI is observed.
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Rotterdam consensus (Supplemental Figure 1), no signif-
icant differences were observed in insulin sensitivity or
body composition between each group. It seems reason-
able toargue that this strategyof subphenotypingofPCOS
patients may not accurately predict those at highest met-
abolic risk. Admittedly, theAEAnov PCOgroup com-
prised most patients, but a similar distribution of PCOS
patients was also noted by Barber et al (31). Interestingly,
Barber et al found that patients in their AEAnovPCO
subgroupweremore insulin resistant; however, thegroups
werenotBMImatched,unlike inour study.For this reason
we believe that comeasurement of A and T might offer a
better alternative in terms of metabolic risk prediction
than the previously suggested categorization by phenotype.
It is crucial that PCOS patients are correctly and accu-
rately categorized as normoandrogenemic or hyperandro-
genemic if they are to be stratified into low- and high-risk
metabolic groups on this basis. Our data show that the
measurement of serum T alone fails to adequately make
this differentiation. Elaborate investigative tools such as
LH stimulation testing or 24-hour urinary androgen me-
tabolite excretion are not universally available in routine
clinical practice. By contrast, concurrent measurement of
serumTandAprovides a suitable alternative. In our view,
only those with normal serum levels of both androgens
should be categorized as normoandrogenemic; as dis-
cussed above, even this cohort may still exhibit occult hy-
perandrogenism, and without prospective studies it is im-
possible to be certain whether they are protected from
more severemetabolic disease over time.Todate, there are
only very limited data on the effects of androgen-lowering
therapies on metabolic parameters in PCOS (35, 36), and
clearly larger prospective trials are needed.
Only 65% of our patients had elevated serum T,
whereas 88% had serum A concentrations above the ref-
erence range. In addition, more than two thirds of the
women initially categorized as normoandrogenemic on
the basis of a normal T had androgen excess as docu-
mented by increased serum A levels, revealing that the
proportion of patients with biochemical androgen excess
is significantly larger than previously reported (19). Based
on the supposition that none of our controls have occult
PCOS, this translates into a sensitivity of 88.3% (95%CI
79.7–94.3%) and a specificity of 97.7% (95% CI 87.7–
99.6%) for A to detect androgen excess. Sensitivity and
specificity values for T of 65.1% (95% CI 54.1–75.1%)
and 88.3% (95% CI 74.9–96.1%) are less impressive. If
we consider the age-related normative reference values
for A in 985 women described by Haring et al (37), the
demarcation between the two groups would improve
the sensitivity even further, with minimum reduction of
specificity.
Although serum LH values increased across each sub-
group, no significant difference was observed between
NA/NT women and healthy controls. We would not rec-
ommend the use of LH or the LH to FSH ratio as inves-
tigative tools in a routine PCOS workup. LH values fluc-
tuatewidely across themenstrual cycle andaccurate blood
sampling is inconsistently timed in the early follicular
phase. It is also very unreliable in women with oligo-ovu-
lation (29). Similarly, fasting insulin levels andHOMA-IR
values were noted to increase across each androgenemic
subgroup; however, these surrogate markers in isolation
clearly cannot be used as a diagnostic marker for PCOS
due to poor specificity, failing to accurately differentiate
between PCOS-driven and multifactorial insulin resis-
tance (7).
There have beenmany attempts over the last 25 years
to define PCOS (1, 4, 5). Each definition focuses on
hyperandrogenism and hyperandrogenemia, yet few at-
tempts have been made to precisely define either term,
and biochemical definitions remain particularly elusive.
Previous work has advocated measurement of a single
morning serum T sample during the early follicular
phase as the diagnostic criterion for hyperandrogen-
emia (9). The limitations of total T as a solitary diag-
nostic tool for hyperandrogenemia have been described
above. The clearance and bioavailability of T are af-
fected by serum SHBG levels, which are lowered by
hyperinsulinemia, but A levels are not affected by this
phenomenon (38), and this may explain some of the
observed discrepancies between T andAmeasurements.
Appropriateness and reliability of analytical methods
has equally been a major issue in this debate, and The
Endocrine Society has appealed to international labo-
ratories to refine techniques for androgen measurement
in women (39). However, the advent of LC/MS-MS has
dramatically improved the rapid detection and reliable
quantification of serum steroids in both clinical and
research practice (40). Accurate A measurement could
Figure 2. Relationship of serum T and A with stratification of
androgenemic subgroups: NA/NT (n  10); HA/NT (n  20); and HA/
HT (n  56). No individuals were identified with NA/HT (n  0).
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now emerge from these developments as a sensitive di-
agnostic test for hyperandrogenemia in PCOS.
Patterns of body fat distribution onDXA did not differ
between PCOS and control patients, supporting previ-
ously published work (41), nor were there differences in
fat distribution between the androgenemic subgroups.
These and other studies point toward a qualitative rather
than quantitative defect in adipose biology in PCOS (42).
17-HSD5 is expressed in adipose tissue, and significant
extraovarian conversion to T may occur in obesity (18).
17-HSD5 is also highly expressed in the ovary, and ac-
tivating variants result in a PCOS phenotype with severe
insulin resistance (43). This suggests a possible primary
role for androgen excess in insulin resistance. However,
the association of insulin resistance and hyperandro-
genism could equally point toward an insulin-mediated
effect on ovarian thecal steroidogenesis. The observation
that insulin plays a key role in thecal androgen generation
in vivo and in vitro supports this hypothesis (44, 45). In-
sulin-stimulated A generation from the ovarian thecamay
create an enlarged circulating pool
for conversion toT, and elevated lev-
els of the former may therefore be a
surrogate marker for metabolic
dysfunction.
A is also produced in significant
quantities by the adrenal gland, but so
far, studies on the impact of hyperin-
sulinismonadrenal androgenproduc-
tion are lacking. Impaired DHEA
sulfation due to 3-phosphoadenosine
5-phosphosulfate synthase-2 defi-
ciency has been shown to result in a
PCOS phenotype (46). A recent pa-
per described two sulfotransferase-
2A1 genetic variants that were asso-
ciated with an increase in the DHEA
to DHEAS ratio in a large PCOS co-
hort (47); in our cohort, 10% of the
PCOS patients were found to have a
highly elevated DHEA level but low
normal serum DHEAS, indicative of
reduced DHEA sulfation capacity.
One limitation of our study is its
cross-sectional nature. Whether the
concurrent presence of elevatedA and
T corresponds to an increased risk of
cardiovascular disease or aworse out-
come in terms of hard clinical end
points can be ascertained only by pro-
spective studies. Longitudinal studies
will reveal whether initial increases in
androgenprecursors later followedby
additional increases inTmay represent a sequence over time
in individual patients. AlthoughHOMA-IRmeasurement is
a limited marker of insulin resistance, the ISI devised by Ce-
derholm and Wibell (25) calculated in our cohort has been
shown to perform with comparable accuracy to a hyperin-
sulinemiceuglycemicclamp(	R0.8). Similarly, itwasnot
possible to measure serum androgens in the early follicular
phase of all patients, largely due to the fact that most PCOS
patients were oligo- or amenorrhoeic. Finally, the debate
over what constitutes normal androgen values continues,
and quoted reference ranges refer to normative values in
95% of an unselected presumptively healthy female popu-
lation, implying that abnormal levelswill be observed in 5%
of women with no evidence of endocrinopathy.
In conclusion, these data endorse the hypothesis that
increasing androgen burden is associated with an adverse
metabolic phenotype and that concurrentmeasurement of
both A and T highlights a PCOS cohort that appears to be
at increasedmetabolic risk.We also believe on the basis of
Figure 3. Total androgen metabolites (A), HOMA-IR (B), ISI (C), fasting insulin (D), serum
DHEA (E), and DHEAS (F) in the three androgen phenotype PCOS subgroups and healthy
controls. *, P  .05; **, P  .01; ***, P  .001.
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these data that serum A is a more sensitive indicator of
PCOS-related androgen excess than serum total T con-
centrations. Theutility of this novel strategy for predicting
metabolic risk in PCOS women warrants investigation in
prospective and longitudinal studies and these may ulti-
mately afford apersonalized approach to themanagement
of PCOS.
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